Market research
IMV.TO IMV Inc
TO CAD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 13M
- P/E ratio
- Not available
- Analyst target
- 37.4
- Dividend yield
- 0.0%
- Beta
- 1.52
Profile
Company facts
- Exchange
- TO
- Currency
- CAD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- CA44974L1031
- Market cap
- 13M
- P/E ratio
- Not available
- Analyst target
- 37.4
- Dividend yield
- 0.0%
- Beta
- 1.52
About
About IMV Inc
IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and MSI-H solid tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the IMV.TO discussion.
5 years, 4 months ago
IMV Inc is currently in a long term downtrend where the price is trading 34.0% below its 200 day moving average.
From a valuation standpoint, the stock is 7878.5% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 81412.1.
IMV Inc's total revenue rose by 169.7% to $89K since the same quarter in the previous year.
Its net income has dropped by 13.2% to $-10M since the same quarter in the previous year.
Finally, its free cash flow fell by 2.0% to $-8M since the same quarter in the previous year.
Based on the above factors, IMV Inc gets an overall score of 1/5.